QuidelOrtho Corporation reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 28, 2025. For Q4 2025, total revenue was USD 724 million. Non-respiratory revenue reached USD 600 million, with Labs revenue growing 8%. Respiratory revenue was USD 123 million, reflecting a 14% decrease primarily due to lower COVID-19 testing, while flu revenue grew 6%. The company reported a GAAP net loss of USD 131 million and a GAAP operating loss of USD 66 million for the quarter. GAAP operating cash flow was USD 132 million, and free cash flow was USD 87 million. QuidelOrtho highlighted continued growth in its Labs, Immunohematology, and Cardiac businesses, and achieved a 240 basis point expansion in adjusted EBITDA margin for FY 2025. Cost-savings initiatives resulted in USD 140 million in savings by the end of the year. The company expects further growth and margin expansion in FY 2026, with free cash flow projected to improve by over USD 200 million. Additionally, QuidelOrtho announced that Chief Financial Officer Joseph M. Busky will retire effective June 30, 2026, and will serve in an advisory role to facilitate the transition.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001906324-26-000003), on February 11, 2026, and is solely responsible for the information contained therein.
Comments